Navigation Links
ImClone Systems Showcases Extensive Research and Development,Program at the AACR Annual Meeting

other monoclonal antibodies, have different biological effects. (#336 Meira et al. Differences in activity between matuzumab and cetuximab in A431 cells may rely on MAPK cascade inhibition.)

-- Emerging biomarkers may serve as predictors of clinical response to ERBITUX. (#5670 Ford et al. Expression of epiregulin and amphiregulin and K-RAS mutation status may predict disease control in metastatic colorectal cancer patients treated with cetuximab (ERBITUX(R)); #5671 Lievre et al. K-RAS mutation in colorectal cancer is a predictive factor of response and progression free survival in patients treated with cetuximab.)

-- It is well established that the combination of ERBITUX and irinotecan can overcome irinotecan resistance in chemotherapy refractory patients with mCRC (Cunningham et al, N Engl J Med. 2004;351:337.) Results presented by Deevi et al. show that ERBITUX may also reverse oxaliplatin resistance. (#2329 Deevi et al. Mechanism for the benefits of cetuximab in combination with oxaliplatin, in oxaliplatin sensitive and resistant colon cancer cell lines.)

-- It is also well established that ERBITUX in combination with radiation therapy improves survival in patients with locally advanced head and neck cancer (Bonner et al, N Engl J Med. 2006;354:567.) In vitro studies presented show enhanced anticancer effects with ERBITUX in combination with radiation in non-small cell lung cancer cells and in combination with HDAC or Src inhibition in colon cancer cells. (#3111 Brooks et al. Targeting EGFR signaling to enhance response of non-small cell lung cancer cells to radiation; #683 LaBonte et al. The effects of histone deacetylase inhibitors on epidermal growth factor receptor expression in colon cancer cell lines: implications for combination therapy; #4079 Kopetz et al. Synergistic activity of Src and EGFR inhibitors in colon cancer.)

ImClone's broad portfolio of investigational fully human IgG1 monoclonal antibodies was featured in 14 AACR
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
2. When Volume Matters, Immunoassay Systems Deliver
3. Genetic Analysis Systems Enter the Clinical Mainstream
4. New Quality Control Systems for Every Laboratory Application
5. Immunoassay Systems - Your Laboratory Workhorse
6. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
7. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
8. NIEHS Researchers Identify Enzyme Critical in DNA Replication
9. Stanford Researchers Find Brain Pathway of Depression in Rats
10. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
11. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
Post Your Comments:
(Date:5/18/2013)... YORK , May 18, 2013 ... law firm, is investigating potential securities fraud at ... AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... Company and its executives violated federal securities laws ... the Company,s Phase III drug trials for Tivopath ...
(Date:5/17/2013)... -- Medical devices are any medical items that are ... of their different mechanisms, actions and regulatory requirements, medical ... drug trails due to their unique clinical practices. Currently, ... both safety and efficacy (which is left to the ... as the SFDA) evaluate MDs for both safety and ...
(Date:5/17/2013)... 17, 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; ... Technology Small Business Technology Transfer Research (STTR) grant ... Infectious Diseases (NIAID), a division of the National ... novel human antibody therapeutics to combat Staphylococcus ... infections, including methicillin-resistant S. aureus (MRSA), ...
Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2Statistical Challenges in Medical Device Trail Evaluation 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4
... DALLAS , March 22 Texas Instruments Incorporated ... in a family of fully integrated analog front ends (AFEs) ... (EEG) equipment, as well as patient monitoring and consumer medical ... and power consumption by up to 95 percent as compared ...
... , March 22 Galderma Laboratories, L.P. today announced the U.S. Food and Drug Administration (FDA) approval of Differin® (adapalene) Lotion, 0.1%, ... April 2010 . , ... , ... ...
Cached Medicine Technology:Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 2Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 3Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 4Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 5Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 6Texas Instruments unveils fully integrated analog front end for ECG and EEG applications 7Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 2Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 3Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 4Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 5Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 6Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation 7
(Date:5/19/2013)... People in Minnesota have a great option ... offering its 28 Day Fat Loss Formula. The best ... of their own home. The product sells for $135 dollars ... be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is ... now, but after using the 28 Day Fat Loss Formula ...
(Date:5/19/2013)... New York, New York (PRWEB) May 19, 2013 ... move forward in a federal litigation now underway in ... to a Case Management Order dated May 3rd, the ... the Bellwether Nominee Pool to eight cases rather than ... litigation is scheduled for Thursday, May 23rd. (In re: ...
(Date:5/19/2013)... Park City, Utah (PRWEB) May 19, 2013 ... new information on small business health insurance ... alternatives to traditional employer sponsored health benefits, is ... contribution and health reimbursement arrangements . ... businesses, start-ups, and the self-employed intrinsically know the ...
(Date:5/19/2013)... According to a new market research ... – 2018): By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), ... Contact IS, Infrared, X-Ray) And Geography" published by ... $8.00 billion in 2012 and is expected to ... CAGR of 3.84% from 2013 to 2018. In ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 These ... for US, UK, Spain, Japan, Italy, Germany and ... the molecular diagnostics laboratory practice, as well as ... with significant market impact during the next five ... probe and biochip technologies, test formats, detection methodologies, ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4
... Drizzled with Pink White-Chocolate, CHICAGO, Oct. 8 ... announce its new Pink Ribbon Pretzel available throughout,October, ... resources and emotional support to those touched by,breast ... of,the breast cancer awareness ribbon, and topped with ...
... in the elderly increases the risk of subsequent mental ... intellectual decline, University of Rochester Medical Center psychiatrists and ... or prevention of depression would reduce or prevent cognitive ... that would be our hope, said Jeffrey M. Lyness, ...
... risk, experts say , , MONDAY, Oct. 8 (HealthDay News) -- ... fertilizer, according to a new study that finds human urine ... , The "yuck" factor aside, scientists who used urine to ... may not be a bad idea. , "Urine is a ...
... YORK, Oct. 8 Forest Laboratories, Inc.,(NYSE: ... pharmaceutical,products, will release its Fiscal 2008 Second Quarter ... Tuesday, October 16, 2007. Later that,day, at 10:00 ... where Dr. Lawrence,Olanoff, President and Chief Operating Officer ...
... busy fall season in,full swing, Hands2GO(R), the nation,s first ... against this year,s winter,cold and flu season. Typically, the ... "Regular hand washing, combined with Hands2GO hand sanitizers and ... year," said Francine,Glick, CEO and founder of Hands2GO. "It,s ...
... on the Internet: Thursday, October 11, 2007, 9 AM-4:00 PM, ... on employer-sponsored wellness programs that will work ... new economic model to address overweight and ... well as employers, e.g. Mayo Clinic, Hannaford ...
Cached Medicine News:Health News:Kim & Scott's Gourmet Pretzels(TM) Supports Breast Cancer Organizations With Its New Pink Ribbon Pretzel 2Health News:Depression can foreshadow intellectual decline in older people 2Health News:Human Urine Safe, Productive Fertilizer 2Health News:Human Urine Safe, Productive Fertilizer 3Health News:Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings 2Health News:Hands2GO(R) Hand Sanitizer Offers Alcohol-Free Alternative to Stopping the Spread of Flu at School and Work 2Health News:Hands2GO(R) Hand Sanitizer Offers Alcohol-Free Alternative to Stopping the Spread of Flu at School and Work 3Health News:Webcast Alert: Expert Group Urges Businesses to Get Real About Weight Loss 2
... The instrument includes the ... has increased illumination for ... illumination. The Copeland retinoscope ... handle, and extended battery ...
... stereopsis from 800 to 40 ... young as 2 years of ... from left to right., ,Randot ... Book #1: 200 & 100 ...
... EasyEye is the only handheld non-contact tonometer with ... is streamlined, quiet and now, with constant ... a gentle puff of air. You can prove ... on the patient's hand before you start. ...
... 2000 Phenytoin Assay is a ... use in the quantitative analysis ... or plasma. Kits are packaged ... Roche COBAS MIRA, COBAS MIRA ...
Medicine Products: